Clinical Trials Logo

RCC clinical trials

View clinical trials related to RCC.

Filter by:

NCT ID: NCT06259552 Recruiting - Solid Tumor Clinical Trials

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

SPX-303
Start date: March 20, 2024
Phase: Phase 1
Study type: Interventional

Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.

NCT ID: NCT05931393 Recruiting - Clinical trials for Renal Cell Carcinoma

Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC)

Start date: December 20, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the effects of a higher dose of cabozantinib or the effects of cabozantinib-nivolumab combination in patients with advanced renal cell carcinoma who have progressed on or after receiving cabozantinib treatment. The study will have two parts or "cohorts". - Cohort 1: cabozantinib 80mg daily - Cohort 2: cabozantinib 40mg daily with nivolumab The cohort assignment will be determined by investigator, based on how much cabozantinib the participant is able to safely receive.

NCT ID: NCT05917106 Recruiting - Clinical trials for Renal Cell Carcinoma

Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

Start date: December 26, 2022
Phase:
Study type: Observational [Patient Registry]

To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.

NCT ID: NCT03891485 Recruiting - Clinical trials for Metastatic Renal Cell Carcinoma

Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy

REVOLUTION
Start date: December 2016
Phase:
Study type: Observational

The project aims to identify Nivolumab predictive biomarkers in metastatic renal cancer patients through functional evaluation of peripheral Tregs and NKs. Moreover the efficacy of new CXCR4 antagonists (PCT/IB2011/000120/ EP2528936B1/ US2013/0079292A1) will be ex vivo evaluated in modulating Tregs and NKs function

NCT ID: NCT03875313 Terminated - Colorectal Cancer Clinical Trials

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Start date: May 20, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose polymerase (PARP) inhibitor talazoparib in participants with advanced/metastatic solid tumors.

NCT ID: NCT03652077 Completed - Ovarian Cancer Clinical Trials

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Start date: September 24, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.

NCT ID: NCT03035630 Withdrawn - Kidney Cancer Clinical Trials

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Start date: May 23, 2017
Phase: Phase 2
Study type: Interventional

This is an open label, randomized phase II trial. Eligible subjects will be randomized in a 1:1 ratio and stratified for known prognostics variables to one of two first-line medication treatment arms. Once disease progression has been documented, and following a required inter-line washout period, subjects will receive either second-line medication treatment or discontinue treatment, per discretion of treating investigator.

NCT ID: NCT02974738 Active, not recruiting - Solid Tumor Clinical Trials

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Start date: December 7, 2016
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors

NCT ID: NCT02447887 Terminated - Clinical trials for Metastatic Renal Cell Carcinoma

Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)

Start date: August 14, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II trial of the combination pegylated IFN-alpha 2b with ixazomib in metastatic renal cell carcinoma (mRCC). Researchers believe that by disabling the protein complex NF-kB, which controls the transfer of genetic information; using the study drug Ixazomib, they can promote necrotic cell death of RCC using interferon alpha - 2b. They hypothesize that the combination of ixazomib with IFN will lead to increased necrotic cell death in RCC tumors and consequent clinical benefit to patients. Patients will receive ixazomib capsules and pegylated IFN alfa 2b injection in this research study. Treatments will be given weekly and 4 weeks of treatment make up one cycle.

NCT ID: NCT02293980 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

Start date: November 25, 2014
Phase: Phase 1
Study type: Interventional

PART 1: The primary objective of this study is to identify the maximum tolerated dose (MTD) of MK-3795, formerly called PT2385 and/or the recommended Phase 2 dose (RP2D) of MK-3795 in patients with advanced clear cell renal cell carcinoma (ccRCC). PART 2: The primary objective of this study is to identify the MTD of MK-3795 up to the RP2D, in combination with nivolumab, in patients with advanced ccRCC.As of Amendment 09 (29 Mar 2024), participants with advanced ccRCC will transition from MK-3795 to belzutifan (MK-6482) in combination with nivolumab or belzutifan alone. PART 3: The primary objective of this study is to identify the MTD of MK-3795 up to the RP2D, in combination with cabozantinib tablets, in patients with advanced ccRCC.